A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

Фаза 2/3 Прекращено NCT04378075

Кратко

This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase. After completion of the randomized, placebo-controlled phase, participants may enter a 48-week, long-term, extension phase during which they will receive open-label treatment with vatiquinone.

Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period

Baseline to Week 24 · percent change

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
• Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
• Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
• Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
• A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
• Maintenance TMS in Treatment Resistant Depression — Austin Messner

Все исследования